Experts discuss CTD-ILD guidance and nerandomilast reshape screening, progression monitoring, and multidisciplinary treatment.
Ara Dikranian, MD
Advertisement
Rheumatologist at the Cabrillo Center for Rheumatic Disease
Articles by Ara Dikranian, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Rheumatology Live
1
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head
2
Early Joint Clearance With Bimekizumab Leads to Durable Disease Control in PsA
3
Autoantibody and IFN Burden Correlate With Nipocalimab Response in Sjögren's Disease
4
Nerandomilast Slows Lung Function Decline, Reduces Mortality Risk in Autoimmune ILD Subgroup
5